Earnings
Quarterly and annual results from Swiss- and European-listed companies, and how the market reacts.

BMW Issues Second Profit Warning on Restructuring and Job Cuts
German carmaker BMW cuts its profit margin outlook and reports a drop in third-quarter earnings, citing restructuring costs and declining sales in China.

BNP Paribas Posts Higher Third-Quarter Profit on Investment Banking Strength
The eurozone's largest bank by balance sheet reported a 13.5 percent increase in third-quarter net income, driven by strong performance in corporate and institutional banking.

Straumann Group Reports Third-Quarter Organic Revenue Growth of 9.2%
Straumann Holding AG posted a third-quarter revenue of CHF 667.1 million and reaffirmed its full-year 2026 outlook.

Deutsche Bank Reports Third-Quarter Profit Growth as DWS Misses Estimates
Germany's largest bank posted higher pre-tax and net profits for the third quarter, while its asset management subsidiary DWS saw record client inflows despite missing earnings expectations.

UBS Reports Third-Quarter Profit Rise and Advances Credit Suisse Integration
The Swiss bank posted a pre-tax profit of 3.6 billion dollars for the third quarter, while reporting progress on cost savings and technology migration.

Temenos Third-Quarter Revenue Rises and Raises 2026 Profit Outlook
The Geneva-based software maker reported higher third-quarter revenue and profit that beat market expectations, prompting an upward revision to its 2026 outlook.

Holcim Raises 2026 Profit Outlook After Strong Nine-Month Organic Growth
Holcim Group Services Ltd reported higher organic revenue and recurring EBIT for the first nine months of 2026, driven by margin expansion and increased customer demand.

Holcim Aims to Confirm Raised Full-Year Goals in Third-Quarter Figures
Analysts anticipate double-digit growth in sales and recurring operating profit for Holcim ahead of its third-quarter report on October 23.

Roche Posts 6% Sales Growth in Nine Months Driven by Pharmaceuticals and Diagnostics
F. Hoffmann-La Roche Ltd reports group sales of CHF 46.5 billion for the first nine months of 2026, supported by strong demand for innovative medicines and diagnostics.